Profile of tivantinib and its potential in the treatment of hepatocellular carcinoma: the evidence to date

References

• Fact Sheets by Cancer [webpage on the Internet]All Cancers (Excluding Non-Melanoma Skin Cancer) Estimated Incidence, Mortality and Prevalence Worldwide in 2012 Available from: http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspxAccessed June 12, 2016
   Google Scholar
• DengG-LZengSShenHChemotherapy and target therapy for hepatocellular carcinoma: new advances and challengesWorld J Hepatol20157578779825914779
   PubMed Web of Science ®Google Scholar
• El-SeragHBHepatocellular carcinomaN Engl J Med2011365121118112721992124
   PubMed Web of Science ®Google Scholar
• National Cancer Institute [webpage on the Internet]A Snapshot of Liver Cancers Available from: http://www.cancer.gov/research/progress/snapshots/liverAccessed August 23, 2016
   Google Scholar
• FinnRSDevelopment of molecularly targeted therapies in hepatocellular carcinoma: where do we go now?Clin Cancer Res201016239039720068087
   PubMed Web of Science ®Google Scholar
• ChoYKKimJKKimMYRhimHHanJKSystematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapiesHepatology200949245345919065676
   PubMed Web of Science ®Google Scholar
• NordenstedtHWhiteDLEl-SeragHBThe changing pattern of epidemiology in hepatocellular carcinomaDig Liver Dis201042suppl 3S206S21420547305
   PubMedGoogle Scholar
• ArtinyanAMaileyBSanchez-LuegeNRace, ethnicity, and socioeconomic status influence the survival of patients with hepatocellular carcinoma in the United StatesCancer201011651367137720101732
   PubMed Web of Science ®Google Scholar
• ChengA-LKangY-KChenZEfficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trialLancet Oncol2009101253419095497
   PubMed Web of Science ®Google Scholar
• LlovetJMRicciSMazzaferroVSorafenib in advanced hepatocellular carcinomaN Engl J Med2008359437839018650514
   PubMed Web of Science ®Google Scholar
• ZhaoXTianCPuszykWMOPA1 downregulation is involved in sorafenib-induced apoptosis in hepatocellular carcinomaLab Invest201393181923108376
   PubMed Web of Science ®Google Scholar
• BruixJMerlePGranitoALBA-03Efficacy and safety of regorafenib versus placebo in patients with hepatocellular carcinoma (HCC) progressing on sorafenib: results of the international, randomized phase 3 RESORCE trialAnn Oncol201627suppl 2ii140ii141
   Web of Science ®Google Scholar
• PortaCPaglinoCMedical treatment of unresectable hepatocellular carcinoma: going beyond sorafenibWorld J Hepatol20102310311321160981
   PubMedGoogle Scholar
• MunshiNJeaySLiYARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activityMol Cancer Ther2010961544155320484018
   PubMed Web of Science ®Google Scholar
• CooperCSParkMBlairDGMolecular cloning of a new transforming gene from a chemically transformed human cell lineNature1984311598129336590967
   PubMed Web of Science ®Google Scholar
• BottaroDPRubinJSFalettoDLIdentification of the hepatocyte growth factor receptor as the c-met proto-oncogene productScience199125149958028041846706
   PubMed Web of Science ®Google Scholar
• BirchmeierCGherardiEDevelopmental roles of HGF/SF and its receptor, the c-Met tyrosine kinaseTrends Cell Biol19988104044109789329
   PubMed Web of Science ®Google Scholar
• SonnenbergEMeyerDWeidnerKMBirchmeierCScatter factor/hepatocyte growth factor and its receptor, the c-met tyrosine kinase, can mediate a signal exchange between mesenchyme and epithelia during mouse developmentJ Cell Biol199312312232358408200
   PubMed Web of Science ®Google Scholar
• BirchmeierCBirchmeierWGherardiEVande WoudeGFMet, metastasis, motility and moreNat Rev Mol Cell Biol200341291592514685170
   PubMed Web of Science ®Google Scholar
• BlumenscheinGRMillsGBGonzalez-AnguloAMTargeting the hepatocyte growth factor-cMET axis in cancer therapyJ Clin Oncol201230263287329622869872
   PubMed Web of Science ®Google Scholar
• MaPCMaulikGChristensenJSalgiaRc-Met: structure, functions and potential for therapeutic inhibitionCancer Metastasis Rev200322430932512884908
   PubMed Web of Science ®Google Scholar
• GaoJJInagakiYXueXQuXJTangWc-Met: a potential therapeutic target for hepatocellular carcinomaDrug Discov Ther20115121122466090
   PubMedGoogle Scholar
• PortaCGiglionePFerrariATivantinib (ARQ197) in hepatocellular carcinomaExpert Rev Anticancer Ther201515661562226035719
   PubMed Web of Science ®Google Scholar
• VenepalliNKGoffLTargeting the HGF-cMET axis in hepatocellular carcinomaInt J Hepatol2013201334163623606971
   PubMedGoogle Scholar
• AuJFrenetteCDevelopment of tivantinib as treatment for hepatocellular carcinomaJ Clin Transl Hepatol201311757826355274
   PubMedGoogle Scholar
• PeyssonnauxCEychèneAThe Raf/MEK/ERK pathway: new concepts of activationBiol Cell2001931–2536211730323
   PubMed Web of Science ®Google Scholar
• EathirajSPalmaRVolckovaEDiscovery of a novel mode of protein kinase inhibition characterized by the mechanism of inhibition of human mesenchymal-epithelial transition factor (c-Met) protein autophosphorylation by ARQ 197J Biol Chem201128623206662067621454604
   PubMed Web of Science ®Google Scholar
• AoyamaAKatayamaROh-haraTSatoSOkunoYFujitaNTivantinib (ARQ 197) exhibits antitumor activity by directly interacting with tubulin and overcomes abc transporter–mediated drug resistanceAm Assoc Cancer Res2014131229782990
   Google Scholar
• BasilicoCPennacchiettiSVignaETivantinib (ARQ197) displays cytotoxic activity that is independent of its ability to bind METAm Assoc Cancer Res201319923812392
   Google Scholar
• KatayamaRAoyamaAYamoriTCytotoxic activity of tivantinib (ARQ 197) is not due solely to c-MET inhibitionCancer Res201373103087309623598276
   PubMed Web of Science ®Google Scholar
• XiangQZhenZDengDYTivantinib induces G2/M arrest and apoptosis by disrupting tubulin polymerization in hepatocellular carcinomaJ Exp Clin Cancer Res20153411826458953
   PubMed Web of Science ®Google Scholar
• Remsing RixLLKuenziBMLuoYGSK3 alpha and beta are new functionally relevant targets of tivantinib in lung cancer cellsACS Chem Biol20149235335824215125
   PubMed Web of Science ®Google Scholar
• TolaneySMTanSGuoHPhase II study of tivantinib (ARQ 197) in patients with metastatic triple-negative breast cancerInvest New Drugs20153351108111426123926
   PubMed Web of Science ®Google Scholar
• SantoroARimassaLBorbathITivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 studyLancet Oncol2013141556323182627
   PubMed Web of Science ®Google Scholar
• LuSRizzaniAKolligsFTAnti-proliferative mechanisms downstream of c-MET of the kinase inhibitor tivantinib (ARQ 197)Hepatology201358S1180A
   Google Scholar
• GuXWangCYuYAbstract #1748: inhibition of HGF/c-Met pathway by ARQ 197: characterization of pharmacodynamic markers in vitro and in vivoCancer Res2009699 suppl174819223555
   PubMed Web of Science ®Google Scholar
• YapTAOlmosDBrunettoATPhase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studiesJ Clin Oncol201129101271127921383285
   PubMed Web of Science ®Google Scholar
• RosenLSSenzerNMekhailTA phase I dose-escalation study of tivantinib (ARQ 197) in adult patients with metastatic solid tumorsClin Cancer Res201117247754776421976535
   PubMed Web of Science ®Google Scholar
• YamamotoNMurakamiHNishinaTThe effect of CYP2C19 polymorphism on the safety, tolerability, and pharmacokinetics of tivantinib (ARQ 197): results from a phase I trial in advanced solid tumorsAnn Oncol20132461653165923413279
   PubMed Web of Science ®Google Scholar
• TherassePArbuckSGEisenhauerEANew guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of CanadaJ Natl Cancer Inst200092320521610655437
   PubMed Web of Science ®Google Scholar
• KubotaTChibaKIgaTFrequency distribution of CYP2C19, CYP2D6, and CYP2C9 mutant-alleles in several different populationsXenobio Metab Dispos2001166974
   Google Scholar
• SantoroASimonelliMRodriguez-LopeCA Phase-1b study of tivantinib (ARQ 197) in adult patients with hepatocellular carcinoma and cirrhosisBr J Cancer20131081212423287988
   PubMed Web of Science ®Google Scholar
• OkusakaTAramakiTInabaYPhase I study of tivantinib in Japanese patients with advanced hepatocellular carcinoma: distinctive pharmacokinetic profiles from other solid tumorsCancer Sci2015106561161725711511
   PubMed Web of Science ®Google Scholar
• PuzanovISosmanJSantoroAPhase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumorsInvest New Drugs201533115916825294187
   PubMed Web of Science ®Google Scholar
• AdjeiAASosmanJAMartellREEfficacy in selected tumor types in a phase I study of the c-MET inhibitor ARQ 197 in combination with sorafenibASCO Meet Abstr20112915_suppl3034
   Google Scholar
• ChaiFAbbadessaGSavageRPhase 1 experience of tivantinib in patients with hepatocellular carcinoma (HCC) or biliary tract cancer (BTC)Ann Oncol2012239 supplix245
   Google Scholar
• GoldmanJWLauxIChaiFPhase 1 dose-escalation trial evaluating the combination of the selective MET (mesenchymal-epithelial transition factor) inhibitor tivantinib (ARQ 197) plus erlotinibCancer2012118235903591122605616
   PubMed Web of Science ®Google Scholar
• ChenC-RSzwayaJRojnuckarinAAbstract #820: combination studies of tyrosine kinase inhibitors (TKIs): assessment of potential cytotoxic synergy of ARQ 197 with sorafenib or sunitinibCancer Res2009699 suppl820
   Google Scholar
• SantoroAPortaCRimassaLMetiv-HCC: a phase III clinical trial evaluating tivantinib (ARQ 197), a MET inhibitor, versus placebo as second-line in patients (pts) with MET-high inoperable hepatocellular carcinoma (HCC)ASCO Meet Abstr20133115_supplTS4159
   Google Scholar
• METIV-HCC_Interim_Analysis_Press_Release__cs.pdf. Available from: http://files.shareholder.com/downloads/ARQL/2313700819x0x882287/84DDD033-9DCA-46B6-9556-D4E90448754B/METIV-HCC_Interim_Analysis_Press_Release__cs.pdfAccessed October 2, 2016
   Google Scholar
• TakaiKHaraJMatsumotoKHepatocyte growth factor is constitutively produced by human bone marrow stromal cells and indirectly promotes hematopoiesisBlood1997895156015659057637
   PubMed Web of Science ®Google Scholar
• Matsuda-HashiiYTakaiKOhtaHHepatocyte growth factor plays roles in the induction and autocrine maintenance of bone marrow stromal cell IL-11, SDF-1 alpha, and stem cell factorExp Hematol2004321095596115504551
   PubMed Web of Science ®Google Scholar
• ZahirHKastrissiosHCarothersTExposure-response relationship to assess the risk of neutropenia in patients with hepatocellular carcinoma (HCC) treated with tivantinibAnn Oncol2012239 supplix244
   Google Scholar
• ArQule [webpage on the Internet]ArQule Provides Updates on Clinical Trials in Hepatocellular Carcinoma and Non-Small Cell Lung Cancer with Tivantinib (NASDAQ:ARQL) Available from: http://investors.arqule.com/releasedetail.cfm?ReleaseID=819847Accessed July 4, 2016
   Google Scholar
• ARQL_News_2014_1_16_General_Releases.pdf. Available from: http://files.shareholder.com/downloads/ARQL/2313700819x0x719482/5FB4DEC7-86CB-411D-8072-F5E523DBFC73/ARQL_News_2014_1_16_General_Releases.pdfAccessed October 6, 2016
   Google Scholar
• UekiTFujimotoJSuzukiTYamamotoHOkamotoEExpression of hepatocyte growth factor and its receptor c-met proto-oncogene in hepatocellular carcinomaHepatology19972548628669096589
   PubMed Web of Science ®Google Scholar
• RimassaLAbbadessaGPersoneniNTumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinibOncotarget Epub2016825
   Google Scholar